

## FINANCIAL TEAR SHEET

### Corporate Profile

Adaptimmune is a leader in the TCR T-cell therapy space focused on developing novel cancer immunotherapy products. We utilize the body's own machinery – the T-cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets - whether intracellular or surface expressed - for administration to patients. We engineer TCRs to increase their affinity to cancer-specific peptides in order to target and potentially destroy cancer cells in patients.

Our wholly-owned pipeline of SPEAR T-cell therapies and targets continues to evolve; SPEAR T-cell therapies targeting MAGE-A10, MAGE-A4, AFP and NY-ESO are moving into and through clinical studies. In addition to the targets for which clinical and preclinical evaluation is ongoing, we continue to build a pipeline of proprietary TCR therapeutic candidates: We have identified over 25 intracellular target peptides preferentially expressed in cancer cells and are currently progressing 12 through unpartnered research programs. We believe these research programs are relevant to a wide range of cancer indications.

We believe our approach will lead to SPEAR therapeutic candidates that have the potential to significantly impact cancer treatment and the clinical outcomes of patients with cancer.

### Primary IR Contact

Investor Contact

**Email:**

[IR@adaptimmune.com](mailto:IR@adaptimmune.com)

# Stock Performance

## ADAP (AMERICAN DEPOSITARY SHARES)

Exchange	NASDAQ GS (US Dollar)
Price	<b>\$12.45</b>
Change (%)	0.00 (0.00%)
Volume	10
52 Week Low	\$4.28
Market Cap	\$7,032,506,502
Rolling EPS	-0.74
PE Ratio	0
Shares Outstanding	564,859,960

Data as of 05/22/18 4:00 p.m. ET



## Recent Headlines & Events

05/16/18

[Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American Association for Clinical Oncology \(ASCO\) Annual Meeting](#)

05/09/18

[Adaptimmune Reports First Quarter 2018 Financial Results and Business Update](#)

04/25/18

[Adaptimmune to Report First Quarter 2018 Financial Results and Business Update on Wednesday May 9, 2018](#)

There are currently no events scheduled.

## SEC Filings

## Corporate Governance

[James Noble](#)

Chief Executive Officer

FILING DATE	FORM	<u>Bent Jakobsen, PhD</u>	Scientific Founder
05/16/18	<u>4</u>	<u>Helen Tayton-Martin, PhD, MBA</u>	Chief Business Officer
05/16/18	<u>4</u>	<u>Rafael Amado, MD</u>	Chief Medical Officer
05/09/18	<u>10-Q</u>	<u>Adrian Rawcliffe</u>	Chief Financial Officer
05/09/18	<u>8-K</u>	<u>Gwendolyn Binder, PhD</u>	Chief Technology Officer
		<u>William (Bill) Bertrand</u>	Chief Operating Officer

Data provided by Nasdaq. Minimum 15 minutes delayed.